Clinical investigation of TROP-2 as an independent biomarker and potential therapeutic target in colon cancer

Zhao,Peng; Yu,Hai‑Zheng; Cai,Jian‑Hui

doi:10.3892/mmr.2015.3900

Clinical investigation of TROP-2 as an independent biomarker and potential therapeutic target in colon cancer

Authors:
- Peng Zhao
- Hai‑Zheng Yu
- Jian‑Hui Cai
View Affiliations

Affiliations: Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Social Sciences, Hebei United University, Tangshan, Hebei 063000, P.R. China
Published online on: June 8, 2015 https://doi.org/10.3892/mmr.2015.3900
Pages: 4364-4369

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colon cancer is associated with a severe demographic and economic burden worldwide. The pathogenesis of colon cancer is highly complex and involves sequential genetic and epigenetic mechanisms. Despite extensive investigation, the pathogenesis of colon cancer remains to be elucidated. As the third most common type of cancer worldwide, the treatment options for colon cancer are currently limited. Human trophoblast cell‑surface marker (TROP‑2), is a cell‑surface transmembrane glycoprotein overexpressed by several types of epithelial carcinoma. In addition, TROP‑2 has been demonstrated to be associated with tumorigenesis and invasiveness in solid types of tumor. The aim of the present study was to investigate the protein expression of TROP‑2 in colon cancer tissues, and further explore the association between the expression of TROP‑2 and clinicopathological features of patients with colon cancer. The expression and localization of the TROP‑2 protein was examined using western blot analysis and immunofluorescence staining. Finally, the expression of TROP‑2 expression was correlated to conventional clinicopathological features of colon cancer using a χ2 test. The results revealed that TROP‑2 protein was expressed at high levels in the colon cancer tissues, which was associated with the development and pathological process of colon cancer. Therefore, TROP‑2 may be used as a biomarker to determine the clinical prognosis, and as a potential therapeutic target in colon cancer.

View Figures

View References

1	Chiang EP, Tsai SY, Kuo YH, et al: Caffeic Acid Derivatives Inhibit the Growth of Colon Cancer: Involvement of the PI3-K/Akt and AMPK Signaling Pathways. PloS One. 9:e996312014. View Article : Google Scholar : PubMed/NCBI
2	Boncheva V, Bonney SA, Brooks SE, et al: New targets for the immunotherapy of colon cancer- does reactive disease hold the answer? Cancer Gene Ther. 20. pp. 157–168. 2013, View Article : Google Scholar
3	Carethers JM, Murali B, Yang B, et al: Influence of Race on Microsatellite Instability and CD8+ T Cell Infiltration in Colon Cancer. PloS One. 9:e1004612014. View Article : Google Scholar : PubMed/NCBI
4	Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, Demirelli F and Serdengecti S: Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumour Biol. 34:2233–2239. 2013. View Article : Google Scholar : PubMed/NCBI
5	Mayer RJ, Garnick MB, Steele GD Jr and Zamcheck N: Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer. 42:1428–1433. 1978. View Article : Google Scholar : PubMed/NCBI
6	Petrioli R, Licchetta A, Roviello G, et al: CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin- based chemotherapy and bevacizumab. Cancer Invest. 30:65–71. 2012. View Article : Google Scholar : PubMed/NCBI
7	Van den Eynden GG, Majeed AW, Illemann M, et al: The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 73:2031–2043. 2013. View Article : Google Scholar : PubMed/NCBI
8	Fong D, Spizzo G, Gostner JM, et al: TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Modern Pathol. 21:186–191. 2008.
9	Pak MG, Shin DH, Lee CH and Lee MK: Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol. 10:532012. View Article : Google Scholar : PubMed/NCBI
10	Fong D, Moser P, Krammel C, et al: High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 99:1290–1295. 2008. View Article : Google Scholar : PubMed/NCBI
11	Mühlmann G, Spizzo G, Gostner J, et al: TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 62:152–158. 2009. View Article : Google Scholar
12	Zhang L, Zhou W, Velculescu VE, et al: Gene expression profiles in normal and cancer cells. Science. 276:1268–1272. 1997. View Article : Google Scholar : PubMed/NCBI
13	Fornaro M, Dell'Arciprete R, Stella M, et al: Cloning of the gene encoding Trop- 2, a cell- surface glycoprotein expressed by human carcinomas. Int J Cancer. 62:610–618. 1995. View Article : Google Scholar : PubMed/NCBI
14	El Sewedy T, Fornaro M and Alberti S: Cloning of the murine TROP2 gene: conservation of a PIP2- binding sequence in the cytoplasmic domain of TROP- 2. Int J Cancer. 75:324–330. 1998. View Article : Google Scholar : PubMed/NCBI
15	Coldren CD, Helfrich BA, Witta SE, et al: Baseline gene expression predicts sensitivity to gefitinib in non- small cell lung cancer cell lines. Mol Cancer Res. 4:521–528. 2006. View Article : Google Scholar : PubMed/NCBI
16	Bignotti E, Todeschini P, Calza S, et al: Trop- 2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 46:944–953. 2010. View Article : Google Scholar : PubMed/NCBI
17	Ambrogi F, Fornili M, Boracchi P, et al: Trop-2 is a determinant of breast cancer survival. PloS One. 9:e969932014. View Article : Google Scholar : PubMed/NCBI
18	Cubas R, Li M, Chen C and Yao Q: Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 1796:309–314. 2009.PubMed/NCBI
19	Varughese J, Cocco E, Bellone S, et al: Uterine serous papillary carcinomas overexpress human trophoblast- cell- surface marker (Trop- 2) and are highly sensitive to immunotherapy with hRS7, a humanized anti- Trop- 2 monoclonal antibody. Cancer. 117:3163–3172. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ripani E, Sacchetti A, Corda D and Alberti S: Human Trop- 2 is a tumor- associated calcium signal transducer. IntJ Cancer. 76:671–676. 1998. View Article : Google Scholar
21	Trerotola M, Li J, Alberti S and Languino LR: Trop- 2 inhibits prostate cancer cell adhesion to fibronectin through the beta1 integrin- RACK1 axis. J Cell Physiol. 227:3670–3677. 2012. View Article : Google Scholar : PubMed/NCBI
22	Trerotola M, Cantanelli P, Guerra E, et al: Upregulation of Trop- 2 quantitatively stimulates human cancer growth. Oncogene. 32:222–233. 2013. View Article : Google Scholar
23	Huang HY: Role of TROP2 in cancer and as potential therapeutic target. Zhonghua Bing Li Xue Za Zhi. 42:860–863. 2013.Article in Chinese.
24	Lu J, Izvolsky KI, Qian J and Cardoso WV: Identification of FGF10 targets in the embryonic lung epithelium during bud morphogenesis. J Biol Chem. 280:4834–4841. 2005. View Article : Google Scholar
25	Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J and Witte ON: Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self- renewal via beta- catenin signaling. Genes Dev. 26:2271–2285. 2012. View Article : Google Scholar : PubMed/NCBI
26	Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP and Witte ON: Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc the Natl Acad Sci USA. 105:20882–20887. 2008. View Article : Google Scholar
27	Antonic V, Stojadinovic A, Kester KE, Weina PJ, Brücher BL, Protic M, Avital I and Izadjoo M: Significance of infectious agents in colorectal cancer development. J Cancer. 4:227–240. 2013. View Article : Google Scholar : PubMed/NCBI
28	Messick CA, Church J, Casey G and Kalady MF: Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum. 52:1535–1541. 2009. View Article : Google Scholar : PubMed/NCBI